Tilray Brands, Inc. (TLRY) earnings date

Nasdaq · Small cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 39 days, typically, give or take 10 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q1 FY2027Thu, Oct 8, 2026before open 38 8-K
Q4 FY2026Tue, Jul 28, 2026after close 58 8-K
Q3 FY2026Wed, Apr 1, 2026before open 32 8-K
Q2 FY2026Thu, Jan 8, 2026after close 39 8-K
Q1 FY2026Thu, Oct 9, 2025before open 39 8-K
Q4 FY2025Mon, Jul 28, 2025after close 58 8-K
Q3 FY2025Tue, Apr 8, 2025before open 39 8-K
Q2 FY2025Fri, Jan 10, 2025before open 41 8-K

What they guided beta

Q1 FY2027 "EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling EXHIBIT 99.1 Tilray Brands Delivers Record Q1 Fiscal 2027 Revenue and Record Q1 Gross Profit, Demonstrating the Power of Its Global Platform, Driven by Double-Digit Year-Over-Year Growth Across International Cannabis, Beverage and Pharmaceutical Distribution First-Quarter Results Reinforce Tilray’s Progress Converting Global Scale, Disciplined Execution and Category Leadership into Higher Revenue, Expanded Gross Profit and Continued Momentum Record First-Quarter Net Revenue of $257 Million, Up 23% Year-Over-Year, with Gross Margin Expanding by" exhibit
Q1 FY2027 "Fiscal Year 2027 Guidance For its fiscal year ending May 31, 2027, the Company reaffirms its expectation to achieve adjusted EBITDA 3 of $68 million to $75 million, representing double-digit growth as compared to fiscal year 2026." exhibit
Q1 FY2027 "Management’s guidance for adjusted EBITDA 3 is provided on a non-GAAP basis and excludes stock-based compensation; change in fair value of contingent consideration; purchase price accounting step-up; impairments of intangible assets and goodwill; other than temporary change in fair value of convertible notes receivable; litigation costs; integration and restructuring costs; transaction-related costs; and other non-operating income (expenses) and non-recurring items that may be incurred during the Company’s fiscal year 2027, which the Company will continue to identify as it reports its future f" exhibit
Q1 FY2027 "The Company cannot reconcile its expected adjusted EBITDA 3 to net income under “Fiscal Year 2027 Guidance” without unreasonable effort because certain items that impact net income and other reconciling metrics are out of the Company’s control and/or cannot be reasonably predicted at this time. ____________________________________________________________________________________________________ (1) Net (debt) cash is a non-GAAP financial measure." exhibit
Q4 FY2026 "EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling EXHIBIT 99.1 Tilray Brands Delivers Record Fiscal 2026 Revenue and Adjusted EBITDA; Demonstrating the Strength of its Diversified Global Platform Across Cannabis, Beverage, Hospitality and Wellness Record Fiscal Year Net Revenue of $ 915 Million, Record Gross Profit, Consistent Adjusted Gross Margin 3 and Record Adjusted EBITDA 5 Highlights the Strength of Tilray’s Scaled Businesses and Profitable Growth Strategy International Medical Cannabis Revenue Increased 34% for the Fiscal Year, Reinforcing Tilray's Leadership Across Europe and Expandin" exhibit
Q4 FY2026 "Simon continued, “As we enter Fiscal 2027, we expect over $1 billion in annual revenue, with a stronger company than ever before." exhibit
Q4 FY2026 "Fiscal Year 2027 Guidance For its fiscal year ending May 31, 2027, the Company expects to achieve adjusted EBITDA 5 of $68 million to $75 million, representing double digit growth as compared to fiscal year 2026." exhibit
Q4 FY2026 "Management’s guidance for adjusted EBITDA 5 is provided on a non-GAAP basis and excludes stock-based compensation; change in fair value of contingent consideration; purchase price accounting step-up; impairments of intangible assets and goodwill; other than temporary change in fair value of convertible notes receivable; litigation costs; integration and restructuring costs; transaction-related costs; and other non-operating income (expenses) and non-recurring items that may be incurred during the Company’s fiscal year 2027, which the Company will continue to identify as it reports its future f" exhibit
Q4 FY2026 "The Company cannot reconcile its expected adjusted EBITDA 5 to net income under “Fiscal Year 2027 Guidance” without unreasonable effort because certain items that impact net income and other reconciling metrics are out of the Company’s control and/or cannot be reasonably predicted at this time. ______________________________ (1) Cash, restricted cash and Marketable Securities is a non-GAAP financial measure." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/TLRY
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/TLRY

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

TLRY earnings date badge

HTML

<a href="https://veritasdata.dev/company/TLRY/"><img src="https://veritasdata.dev/embed/TLRY.svg" alt="TLRY earnings date" width="240" height="56"></a>

Markdown

[![TLRY earnings date](https://veritasdata.dev/embed/TLRY.svg)](https://veritasdata.dev/company/TLRY/)

Script

<script async src="https://veritasdata.dev/embed/TLRY.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/TLRY"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.